Abstract: FR-PO0504
Clinical Outcomes of Hemoadsorption in Rhabdomyolysis
Session Information
- Dialysis: Hemodiafiltration, Ultrafiltration, Profiling, and Interdialytic Symptoms
November 07, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 801 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Jimenez Acosta, Dario Xavier, DIALNEF, Quito, Ecuador
- Jimenez, Jazmin Alejandra, DIALNEF, Quito, Ecuador
Group or Team Name
- GHEMINE Group.
Background
Rhabdomyolysis occurs when skeletal muscle breaks down, releasing myoglobin, creatine kinase (CK), etc., into the bloodstream. The hemoadsorption (HA) technique employs cartridges filled with divinylbenzene and styrene sorbent resin to effectively purify medium and large molecules from this pathology (Fig. 1).
Methods
Observational and retrospective study analyzing the clinical outcomes in severe rhabdomyolysis (myoglobin >5000 ng/ml) treated with Jafron HA 330 cartridges. The goal is to evaluate the effectiveness of removing myoglobin and CK and its impact on the patient's status. Each session lasted four hours and had a 250 ml/min blood flow rate. Lab tests were performed before and after treatment.
Results
Nine patients were analyzed: all men, median age of 21. The HA technique has a zero mortality incidence and demonstrates impressive clearance percentages of the molecules (Table 1). A single HA session was necessary (66%).
Conclusion
The HA technique has proven efficient in removing Myoglobin and CK; however, the potential for removing CK (80,000 Da) is particularly intriguing. We propose two hypotheses. Our first hypothesis suggests the breakage of disulfide bridges in the molecule, allowing for the adsorption of both subunits. The second option, CK, is not adsorbed due to its large size. Instead, it is an early biomarker of muscle damage. We recommend the HA technique be employed early in patients with severe rhabdomyolysis.
Effects of Hemoadsorption on Myoglobin and Creatine Kinase level
| SUBSTANCES OF INTEREST | BLOOD LEVEL |
| MYOGLOBIN | |
| Pre Hemoadsorption, mediana (IQR) | 7.453 (6.523-11.185) |
| Post Hemoadsorption, mediana (IQR) | 2.100 (1.444-3.104) |
| Clearance, % (CI, 95%) | 74,16 (58,71-89,61) |
| CREATINE KINASE | |
| Pre Hemoadsorption, mediana (IQR) | 69.481 (38.319-134.771) |
| Post Hemoadsorption, mediana (IQR) | 16.795 (10.676-32.259) |
| Clearance, % (CI, 95%) | 63,46 (24,77-102,15) |
IQR: interquartile range, CI: Confidence Interval.